stem cell treatment, spinal cord stem cells, stem cell injection spine, spinal cord injury stem cell therapy,

Injured spinal cords repaired using patients’ own stem cells

NEW HAVEN, CT (US), February 2021 — Intravenous injection of bone marrow derived stem cells (MSCs) in patients with spinal cord injuries led to significant improvement in motor functions, researchers from Yale University and Japan report Feb. 18 in the Journal of Clinical Neurology and Neurosurgery.

For more than half of the patients, substantial improvements in key functions — such as ability to walk or to use their hands — were observed within weeks of stem cell injection, the researchers report. No substantial side effects were reported.

The patients had sustained non-penetrating spinal cord injuries, in many cases from falls or minor trauma, several weeks prior to implantation of the stem cells. Their symptoms involved loss of motor function and coordination, sensory loss and bowel and bladder dysfunction. The stem cells were prepared from the patients’ own bone marrow via a culture protocol that took a few weeks in a specialized cell processing center. The cells were injected intravenously in this series, with each patient serving as their own control. Results were not blinded and there were no placebo controls.

Yale scientists Jeffery D. Kocsis, Ph.D., professor of neurology and neuroscience, and Stephen G. Waxman, M.D., Ph.D., professor of neurology, neuroscience and pharmacology, were senior authors of the study, which was carried out with investigators at Sapporo Medical University in Japan. Key investigators of the Sapporo team, Osamu Honmou, M.D., Ph.D,  and Masanori Sasaki, M.D., Ph.D., both hold adjunct professor positions in neurology at Yale.

Drs. Kocsis and Waxman stress that additional studies will be needed to confirm the results of this preliminary, unblinded trial. They also stress that this could take years. Despite the challenges, they remain optimistic.

“Similar results with stem cells in patients with stroke increases our confidence that this approach may be clinically useful,” noted Dr. Kocsis. “This clinical study is the culmination of extensive preclinical laboratory work using MSCs between Yale and Sapporo colleagues over many years.” 

“The idea that we may be able to restore function after injury to the brain and spinal cord using the patient’s own stem cells has intrigued us for years,” Dr. Waxman said. “Now we have a hint, in humans, that it may be possible.”

Learn more:
DOI: 10.1016/j.clineuro.2021.106565